Phase 1-2 study of Lu177-DOTATATE and olaparib in neuroendocrine tumors

Division Of Basic Sciences - Nci

Investigators

Linked publications & trials

Abstract

The rationale behind using combination therapies in cancer stems from the potential of synergistic mechanisms of action of the involved agents. Olaparib is a PARP-inhibitor which blocks the repair of single-stranded DNA breaks and is especially effective when combined with other agents which induces DNA damage. We are proposing a Phase I/II clinical trial to look at the combination of olaparib with the targeted radionuclide agent Lutetium-177-DOTATATE (trade name: Lutathera, Novartis/Advanced Accelerator Appliations) in inoperable gastro-entero-pancreatic neuroendocrine tumors (GEP-NET).